---
title: "First US implants mark start of DurAVR THV early feasibility study"
date: "2023-08-09T11:28:07.000Z"
publishedDate: "9 août 2023"
summary: "Anteris Technologies has reported that its DurAVR biomimetic, single-piece transcatheter aortic valve, has been successfully used to treat patients as part of the DurAVR THV Early Feasibility Study (EFS) in the USA. Azeem Latib (Montefiore Health System, New York, USA) the national principal investigator of the study performed the first group of US DurAVR procedures."
importance: ""
sourceUrl: "https://cardiovascularnews.com/duravr-us-efs-study-commences/"
tags: ["France", "Actualité", "Cardiovascular News — Latest"]
permalink: "/papers/2023-08-09-first-us-implants-mark-start-of-duravr-thv-early-feasibility-study"
imageUrl: "https://cardiovascularnews.com/wp-content/uploads/sites/14/2023/08/Montefiore_Team_DurAVR.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/duravr-us-efs-study-commences/"
---

![First US implants mark start of DurAVR THV early feasibility study](https://cardiovascularnews.com/wp-content/uploads/sites/14/2023/08/Montefiore_Team_DurAVR.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/duravr-us-efs-study-commences/*

## L’essentiel

Anteris Technologies has reported that its DurAVR biomimetic, single-piece transcatheter aortic valve, has been successfully used to treat patients as part of the DurAVR THV Early Feasibility Study (EFS) in the USA. Azeem Latib (Montefiore Health System, New York, USA) the national principal investigator of the study performed the first group of US DurAVR procedures.

## Lien source

https://cardiovascularnews.com/duravr-us-efs-study-commences/
